.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, clients along with metastatic stomach lumps who received biomarker-matched therapies based on flowing growth DNA profiling showed a higher medical advantage than those obtaining unrivaled treatment.